Filter By Category
Archives
Share on -
ANACETRAPIB
Generic Name: ANACETRAPIB
ABSTRACT -
Anacetrapib is a potent cholesteryl ester transfer protein (CETP) inhibitor that raises high-density lipoprotein cholesterol and lowers low-density lipoprotein cholesterol when added to statin therapy. It was investigated for cardiovascular risk reduction but was not broadly marketed, partly because of development decisions and long persistence in adipose tissue.
DOSAGE -
Dosage should be determined only by a qualified healthcare professional.
Anacetrapib is not an approved routine lipid-lowering medicine in most markets.
Large outcome studies evaluated once-daily oral dosing with background statin therapy, but routine use should not occur outside approved protocols.
Monitor lipid profile, liver function, blood pressure, and adverse effects if used in a study setting.
SIDE EFFECTS–
- Possible side effects include:
- Headache
- Nasopharyngitis
- Diarrhoea
- Nausea
- Muscle symptoms
- Blood-pressure changes
- Liver enzyme abnormalities
- Long terminal persistence in tissues
- Potential drug-specific or class-related lipid changes
ALLRGIC REACTIONS–
- Hypersensitivity to anacetrapib or excipients may occur.
- Symptoms may include rash, urticaria, swelling, wheezing, or anaphylaxis.
- Important: Allergic reactions require medical assessment and avoidance of re-exposure unless advised.
DRUG INTERACTIONS–
- Use caution with lipid-lowering combinations, especially statins requiring metabolic review.
- Strong metabolic inhibitors or inducers may alter exposure depending on formulation and route.
- Anticoagulants and antiplatelet therapy should be assessed according to cardiovascular status.
- Patients should inform clinicians about all medicines and supplements.
PREAUTIONS–
- Not recommended for routine clinical use where not approved.
- Use caution in severe hepatic impairment and pregnancy.
- Assess cardiovascular risk and existing guideline-supported lipid therapy first.
- Long tissue persistence should be considered when stopping or planning pregnancy.
WARNINGS –
- Anacetrapib is not a routine approved therapy in most countries.
- Do not substitute it for established lipid-lowering medicines without specialist advice.
- Report unexplained muscle pain, jaundice, severe rash, or persistent gastrointestinal symptoms.
- Keep out of reach of children.
Share on -
. Developed by